Giuseppe Lombardi

Padova, 35128, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 212 publications

Neurocognitive functioning in long-term survivors of glioblastoma, IDH-wildtype and astrocytoma, IDH-mutant, CNS WHO grade 4: A report from EORTC 1419 (ETERNITY).

Neurocognitive functioning in long-term survivors of glioblastoma, IDH-wildtype and astrocytoma, IDH-mutant, CNS WHO grade 4: A report from EORTC 1419 (ETERNITY).

Journal: European journal of cancer (Oxford, England : 1990)

Published: May 30, 2026

Prognostic impact of phosphatase and tensin homolog status in recurrent IDH-wildtype glioblastoma receiving second-line therapy.

Prognostic impact of phosphatase and tensin homolog status in recurrent IDH-wildtype glioblastoma receiving second-line therapy.

Journal: Neuro-oncology advances

Published: April 17, 2026

ESTRO, ESNR and EORTC consensus-based definition for MRI abnormalities after radiotherapy for intracranial central nervous system tumours.

ESTRO, ESNR and EORTC consensus-based definition for MRI abnormalities after radiotherapy for intracranial central nervous system tumours.

Journal: Neuro-oncology

Published: April 13, 2026

Real-World Treatment Pathways of Adult Patients with Glioblastoma and Other CNS Tumors: A Population-Based Registry Study.

Real-World Treatment Pathways of Adult Patients with Glioblastoma and Other CNS Tumors: A Population-Based Registry Study.

Journal: Current oncology (Toronto, Ont.)

Published: March 12, 2026

BRAF-altered glioma in adults and children: A Society for Neuro-Oncology (SNO) and European Society for Neuro-Oncology (EANO) consensus review on clinical management and future directions.

BRAF-altered glioma in adults and children: A Society for Neuro-Oncology (SNO) and European Society for Neuro-Oncology (EANO) consensus review on clinical management and future directions.

Journal: Neuro-oncology

Published: March 09, 2026

Prolonged sequential temozolomide in glioblastoma: A systematic review with exploratory quantitative synthesis.

Prolonged sequential temozolomide in glioblastoma: A systematic review with exploratory quantitative synthesis.

Journal: Cancer treatment and research communications

Published: February 17, 2026

Molecular profiling and access to treatment for rare cancers in Europe.

Molecular profiling and access to treatment for rare cancers in Europe.

Journal: Nature communications

Published: January 22, 2026

Reasons driving choice and clinical course of patients with CNS WHO grade 3 IDH mutant glioma receiving vorasidenib after surgery: a pilot experience.

Reasons driving choice and clinical course of patients with CNS WHO grade 3 IDH mutant glioma receiving vorasidenib after surgery: a pilot experience.

Journal: Journal of neuro-oncology

Published: January 08, 2026

STELLAR: Phase III, Randomized, Open-Label Study of Eflornithine Plus Lomustine Versus Lomustine Alone in Patients With Recurrent Grade 3 Astrocytoma.

STELLAR: Phase III, Randomized, Open-Label Study of Eflornithine Plus Lomustine Versus Lomustine Alone in Patients With Recurrent Grade 3 Astrocytoma.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: December 01, 2025

The role of the molecular tumor board: learnings from the ROME trial.

The role of the molecular tumor board: learnings from the ROME trial.

Journal: NPJ precision oncology

Published: November 18, 2025

Targeted and systemic therapies for recurrent adult ependymomas: real-world outcomes from a single institution and concise literature review.

Targeted and systemic therapies for recurrent adult ependymomas: real-world outcomes from a single institution and concise literature review.

Journal: Frontiers in oncology

Published: November 17, 2025

Targeted therapies in optic pathway gliomas.

Targeted therapies in optic pathway gliomas.

Journal: Cancer treatment reviews

Published: November 13, 2025

Showing 1-12 of 212

Last Updated: 09/26/2026